Details of the Drug Combination

General Information of Drug Combination (ID: DCCY3JR)

Drug Combination Name
Indocyanine green Isosulfan blue
Indication
Disease Entry Status REF
Endometrial Cancer Phase 1 [1]
Component Drugs Indocyanine green   DM2NQUY Isosulfan blue   DMLUDO8
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Indocyanine green
Disease Entry ICD 11 Status REF
Gastrointestinal disease DE2Z Approved [2]
Indocyanine green Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [4]
------------------------------------------------------------------------------------
Indication(s) of Isosulfan blue
Disease Entry ICD 11 Status REF
Investigative surgical procedure QB8Z Approved [3]

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Recurrent Melanoma DC8IOOF N. A. Phase 1 [5]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01818739) Lymph Node Mapping in Patients With Endometrial Cancer
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4844).
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Primovist, Eovist: what to expect? J Hepatol. 2012 Aug;57(2):421-9.
5 ClinicalTrials.gov (NCT01898403) Lymph Node Mapping Using Indocyanine Green Solution in Diagnosing Patients With Malignant Melanoma